Profile data is unavailable for this security.
About the company
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company’s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
- Revenue in AUD (TTM)16.49m
- Net income in AUD-18.04m
- Incorporated2001
- Employees--
- LocationGenetic Signatures LtdHeart Research Institute7 Eliza Street NewtownSYDNEY 2042AustraliaAUS
- Phone+61 29870-7580
- Fax+61 29240-9821
- Websitehttps://geneticsignatures.com/au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurotech International Ltd | 1.28m | -4.98m | 79.36m | -- | -- | 14.51 | -- | 62.12 | -0.0058 | -0.0058 | 0.0015 | 0.0054 | 0.1826 | -0.1149 | 5.67 | -- | -71.23 | -197.33 | -74.66 | -255.24 | 100.07 | 79.57 | -390.03 | -1,043.88 | 18.35 | -- | 0.00 | -- | 106.22 | 83.24 | -131.75 | -- | -- | -- |
| Imricor Medical Systems Inc | 921.93k | -33.89m | 93.17m | -- | -- | -- | -- | 101.06 | -0.2153 | -0.2153 | 0.0059 | -0.0776 | 0.0559 | 0.8749 | 2.38 | -- | -205.60 | -93.47 | -294.49 | -106.30 | -181.27 | -134.71 | -3,675.60 | -2,462.89 | 0.4944 | -3.64 | 15.92 | -- | -24.56 | -9.29 | -30.36 | -- | -10.82 | -- |
| SDI Ltd | 109.61m | 8.04m | 98.66m | 300.00 | 12.27 | 1.11 | 7.99 | 0.9001 | 0.0676 | 0.0676 | 0.9221 | 0.7494 | 0.8449 | 1.69 | 6.22 | -- | 6.20 | 7.27 | 7.46 | 8.40 | 59.28 | 59.79 | 7.34 | 8.07 | 1.26 | 10.37 | 0.2318 | 51.85 | 13.35 | 7.67 | -3.09 | 4.50 | 52.58 | 5.39 |
| Genetic Signatures Ltd | 16.49m | -18.04m | 139.89m | -- | -- | 3.45 | -- | 8.48 | -0.1245 | -0.1245 | 0.1136 | 0.2172 | 0.3366 | 1.06 | 5.25 | -- | -36.81 | -7.14 | -40.19 | -7.82 | 40.66 | 57.68 | -109.38 | -13.74 | 5.95 | -18,040.00 | 0.0003 | -- | -38.11 | 33.44 | -558.77 | -- | 73.20 | -- |
| Cyclopharm Limited | 32.21m | -4.70m | 150.70m | 87.00 | -- | 4.67 | -- | 4.68 | -0.0508 | -0.0508 | 0.3476 | 0.3428 | 0.6748 | 1.11 | 4.13 | 370,173.10 | -9.85 | -12.60 | -11.92 | -14.94 | 68.15 | 70.20 | -14.60 | -25.47 | 2.32 | -18.40 | 0.1159 | -- | 11.22 | 15.50 | 28.90 | -- | -7.83 | -- |
| EMvision Medical Devices Ltd | 8.86m | -3.22m | 162.31m | -- | -- | 25.94 | -- | 18.32 | -0.0449 | -0.0449 | 0.1186 | 0.0733 | 0.7954 | -- | -- | -- | -28.95 | -67.20 | -45.25 | -79.38 | -- | -- | -36.40 | -175.99 | -- | -35.20 | 0.3424 | -- | 62.08 | 70.47 | 36.64 | -- | -- | -- |
| Mach7 Technologies Ltd | 26.97m | -5.55m | 162.84m | 90.00 | -- | 2.99 | 75.24 | 6.04 | -0.0231 | -0.0231 | 0.1123 | 0.2256 | 0.3605 | -- | 3.21 | -- | -7.42 | -7.48 | -8.73 | -8.65 | 95.09 | 93.72 | -20.59 | -20.56 | -- | -2,605.17 | 0.0193 | -- | 10.97 | 28.30 | 74.85 | -- | 29.28 | -- |
| Aroa Biosurgery Ltd | 60.39m | -7.60m | 170.38m | 261.00 | -- | 1.91 | -- | 2.82 | -0.0221 | -0.0221 | 0.1759 | 0.2592 | 0.5764 | 1.69 | 3.18 | 231,369.40 | -7.25 | -9.60 | -7.88 | -12.08 | 84.47 | 77.32 | -12.58 | -18.98 | 7.09 | -12.52 | 0.065 | -- | 59.68 | 41.68 | 95.28 | -- | 35.28 | -- |
| ImpediMed Ltd | 10.47m | -19.42m | 180.06m | 76.00 | -- | 3.53 | -- | 17.19 | -0.0102 | -0.0102 | 0.0055 | 0.0252 | 0.1961 | 1.32 | 4.41 | 137,802.60 | -36.37 | -52.27 | -40.94 | -62.34 | 86.95 | 80.64 | -185.47 | -264.76 | 6.85 | -- | 0.0244 | -- | 7.36 | 27.87 | -3.26 | -- | 37.83 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perennial Value Management Ltd.as of 25 Jan 2024 | 23.32m | 12.50% |
| FIL Investment Management (Hong Kong) Ltd.as of 28 Aug 2023 | 11.23m | 6.02% |
| Regal Funds Management Pty Ltd.as of 03 May 2024 | 9.28m | 4.98% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 4.77m | 2.56% |
| Pengana Capital Ltd.as of 30 Nov 2023 | 453.28k | 0.24% |
| DFA Australia Ltd.as of 31 Mar 2024 | 367.95k | 0.20% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 210.69k | 0.11% |
| FIL Investment Advisorsas of 28 Aug 2023 | 15.65k | 0.01% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2023 | 9.26k | 0.01% |
